Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. BVAXF


Primary Symbol: C.BIOV

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Post by Rossaporinoon Jan 24, 2022 9:22am
113 Views
Post# 34351758

Test

Test

One way to avoid perhaps unnecessary revaccination and individualize booster doses would be to measure the cellular immunity of each person . This is what the immunologist Yvelise Barrios and the allergist Vctor Matheu are already doing, the two doctors at the University Hospital of the Canary Islands who have developed a skin test that detects if we have specific T cells to fight covid-19 by means of a superficial 

At the moment, this test is serving to help in the consultation they have created to evaluate the immune response to covid, aimed at the most vulnerable patients such as immunosuppressed people, whose immune status is monitored after the third dose. However, we will still have to wait "a few months" for this test to be used on a large scale.
 

https://www.20minutos.es/noticia/4943373/0/test-cutaneo-inmunidad-proteccion-covid-vacunas-uso-racional/

<< Previous
Bullboard Posts
Next >>